57 related articles for article (PubMed ID: 33773263)
21. [Evaluation of the Clinical Efficacy and Prognosis of Long-Term Maintenance Lenalidomide Therapy in Patients with Multiple Myeloma].
Luo M; Hu LW; Gu XK; Lan H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):540-546. PubMed ID: 33812428
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Bachmann F; Schreder M; Engelhardt M; Langer C; Wolleschak D; Mügge LO; Dürk H; Schäfer-Eckart K; Blau IW; Gramatzki M; Liebisch P; Grube M; V Metzler I; Bassermann F; Metzner B; Röllig C; Hertenstein B; Khandanpour C; Dechow T; Hebart H; Jung W; Theurich S; Maschmeyer G; Salwender H; Hess G; Bittrich M; Rasche L; Brioli A; Eckardt KU; Straka C; Held S; Einsele H; Knop S
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809431
[TBL] [Abstract][Full Text] [Related]
23. Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study.
Terpos E; Ntanasis-Stathopoulos I; Katodritou E; Kyrtsonis MC; Douka V; Spanoudakis E; Papatheodorou A; Eleutherakis-Papaiakovou E; Kanellias N; Gavriatopoulou M; Makras P; Kastritis E; Dimopoulos MA
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809268
[TBL] [Abstract][Full Text] [Related]
24. Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Saafan H; Alahdab A; Michelet R; Gohlke L; Ziemann J; Holdenrieder S; McLaughlin KM; Wass MN; Cinatl J; Michaelis M; Kloft C; Ritter CA
Cells; 2021 Mar; 10(4):. PubMed ID: 33804833
[TBL] [Abstract][Full Text] [Related]
25. Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.
Finch CL; Dyall J; Xu S; Nelson EA; Postnikova E; Liang JY; Zhou H; DeWald LE; Thomas CJ; Wang A; Xu X; Hughes E; Morris PJ; Mirsalis JC; Nguyen LH; Arolfo MP; Koci B; Holbrook MR; Hensley LE; Jahrling PB; Schmaljohn C; Johansen LM; Olinger GG; Schiffer JT; White JM
Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33801811
[TBL] [Abstract][Full Text] [Related]
26. Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS.
Kapara A; Findlay Paterson KA; Brunton VG; Graham D; Zagnoni M; Faulds K
Anal Chem; 2021 Apr; 93(14):5862-5871. PubMed ID: 33797884
[TBL] [Abstract][Full Text] [Related]
27. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
28. β-Lactone Derivatives and Their Anticancer Activities: A Short Review.
Wang J; Shi Y; Jiang D
Curr Top Med Chem; 2021; 21(18):1645-1656. PubMed ID: 33797384
[TBL] [Abstract][Full Text] [Related]
29. Native Mass Spectrometry for the Study of PROTAC GNE-987-Containing Ternary Complexes.
Sternicki LM; Nonomiya J; Liu M; Mulvihill MM; Quinn RJ
ChemMedChem; 2021 Jul; 16(14):2206-2210. PubMed ID: 33792163
[TBL] [Abstract][Full Text] [Related]
30. Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ
Li X; Dong L; Liu J; Wang C; Zhang Y; Mei Q; Han W; Xie P; Nie J
Front Cell Dev Biol; 2021; 9():647713. PubMed ID: 33791306
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D
Lee HK; Noh MH; Hong SW; Kim SM; Kim SH; Kim YS; Broaddus VC; Hur DY
Anticancer Res; 2021 Mar; 41(3):1261-1269. PubMed ID: 33788717
[TBL] [Abstract][Full Text] [Related]
32. The capacity of CD4
Holmen Olofsson G; Pedersen SR; Aehnlich P; Svane IM; Idorn M; Thor Straten P
Cytotherapy; 2021 Jul; 23(7):582-589. PubMed ID: 33785258
[TBL] [Abstract][Full Text] [Related]
33. DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Zhang X; Luukkonen LM; Eissler CL; Crowley VM; Yamashita Y; Schafroth MA; Kikuchi S; Weinstein DS; Symons KT; Nordin BE; Rodriguez JL; Wucherpfennig TG; Bauer LG; Dix MM; Stamos D; Kinsella TM; Simon GM; Baltgalvis KA; Cravatt BF
J Am Chem Soc; 2021 Apr; 143(13):5141-5149. PubMed ID: 33783207
[TBL] [Abstract][Full Text] [Related]
34. A male with primary accessory breast carcinoma in an axilla is strongly suspected of having hereditary breast cancer.
Takahashi E; Terata K; Nanjo H; Ishiyama K; Hiroshima Y; Yamaguchi A; Yatsuyanagi M; Kudo C; Wakita A; Takashima S; Sato Y; Imai K; Motoyama S; Minamiya Y
Int Cancer Conf J; 2021 Apr; 10(2):107-111. PubMed ID: 33782642
[TBL] [Abstract][Full Text] [Related]
35. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.
Cornell RF; Fraser R; Costa L; Goodman S; Estrada-Merly N; Lee C; Hildebrandt G; Gergis U; Farhadfar N; Freytes CO; Kamble RT; Krem M; Kyle RA; Lazarus HM; Marks DI; Meehan K; Patel SS; Ramanathan M; Olsson RF; Wagner JL; Kumar S; Qazilbash MH; Shah N; Hari P; D'Souza A
Transplant Cell Ther; 2021 Mar; 27(3):264.e1-264.e7. PubMed ID: 33781533
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.
Blommestein HM; Franken MG; van Beurden-Tan CHY; Blijlevens NMA; Huijgens PC; Sonneveld P; Uyl-de Groot CA; Zweegman S
JAMA Netw Open; 2021 Mar; 4(3):e213497. PubMed ID: 33779744
[TBL] [Abstract][Full Text] [Related]
38. Association between Vitamin D Supplements, Oxidative Stress Biomarkers, and Hyperbaric Therapy in Patients with Sudden Sensorineural Hearing Loss.
Paprocki J; Sutkowy P; Piechocki J; Woźniak A
Oxid Med Cell Longev; 2021; 2021():8895323. PubMed ID: 33777323
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.
Chan You S; Krumholz HM; Suchard MA; Schuemie MJ; Hripcsak G; Chen R; Shea S; Duke J; Pratt N; Reich CG; Madigan D; Ryan PB; Woong Park R; Park S
Hypertension; 2021 May; 77(5):1528-1538. PubMed ID: 33775125
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, Antifungal Activity, 3D-QSAR, and Molecular Docking Study of Novel Menthol-Derived 1,2,4-Triazole-thioether Compounds.
Huang M; Duan WG; Lin GS; Li BY
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
